Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2025)
Historic Accumulated Expenses for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $27.0 million.
- Inhibrx Biosciences' Accumulated Expenses fell 979.26% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year decrease of 979.26%. This contributed to the annual value of $29.9 million for FY2024, which is 3096.2% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Accumulated Expenses is $27.0 million, which was down 979.26% from $28.5 million recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Accumulated Expenses peaked at $43.3 million during Q4 2023, and registered a low of $23.9 million during Q2 2024.
- In the last 3 years, Inhibrx Biosciences' Accumulated Expenses had a median value of $29.9 million in 2024 and averaged $30.7 million.
- In the last 5 years, Inhibrx Biosciences' Accumulated Expenses tumbled by 3096.2% in 2024 and then skyrocketed by 1935.46% in 2025.
- Over the past 3 years, Inhibrx Biosciences' Accumulated Expenses (Quarter) stood at $43.3 million in 2023, then plummeted by 30.96% to $29.9 million in 2024, then dropped by 9.79% to $27.0 million in 2025.
- Its Accumulated Expenses stands at $27.0 million for Q3 2025, versus $28.5 million for Q2 2025 and $32.8 million for Q1 2025.